Form 4: Immunocore Director Receives Equity Grant

Director Peter John Ratcliffe was granted 27,492 share options in Immunocore Holdings plc.

Summary

• Director Peter John Ratcliffe received an option grant for 27,492 ordinary shares.
• The options have an exercise price of $28.52 per share.
• The grant date for the transaction was May 27, 2026.
• The options are scheduled to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market price volatility affecting the value of the granted options.
• Vesting is contingent upon the director's continuous service to the company.

Future Outlook

The options vest on the earlier of May 27, 2027, or the day prior to the next annual general meeting, assuming continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term strategic milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard equity compensation packages for directors in mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the day before the next annual general meeting.

Key Dates

Keywords

Immunocore, IMCR, Form 4, Director Compensation, Share Options, Insider Transaction